OLBA HEALTHCARE HOLDINGS Valuation

Q: What is the Fair Price of 2689 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

2689 (¥2021) is trading below our estimate of [[fair value]] (¥7801.24)

Is 2689 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2689 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2689 (¥2021) is trading below our estimate of fair value (¥7801.24)

Significantly Below Fair Value: 2689 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2689?

Key metric: As 2689 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 2689. This is calculated by dividing 2689's market cap by their current earnings.
What is 2689's PE Ratio?
PE Ratio	8x
Earnings	JP¥1.50b
Market Cap	JP¥11.95b

2689 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.1x
Enterprise Value/EBITDA	4.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 2689's PE Ratio compare to its peers?

The above table shows the PE ratio for 2689 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	48.4x
3417 Ohki Healthcare HoldingsLtd	6.2x	n/a	JP¥11.5b
7488 Yagami	11.2x	n/a	JP¥14.1b
3079 DVx	160.8x	n/a	JP¥8.7b
3154 Medius Holdings	15.6x	n/a	JP¥17.3b
2689 OLBA HEALTHCARE HOLDINGS	8x	n/a	JP¥12.0b

Price-To-Earnings vs Peers: 2689 is good value based on its Price-To-Earnings Ratio (8x) compared to the peer average (48.4x).

Price to Earnings Ratio vs Industry

How does 2689's PE Ratio compare vs other companies in the JP Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 2689 is good value based on its Price-To-Earnings Ratio (8x) compared to the JP Healthcare industry average (13.3x).

Price to Earnings Ratio vs Fair Ratio

What is 2689's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2689 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2689's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Daiken Medical

JP¥14.4b

Engages in the manufacture and distribution of medical devices and equipment in Japan and internationally.

7775

JP¥502.00

-0.6%

-3.5%

FINDEX

JP¥20.6b

Offers medical systems, office systems, and Healthtech products in Japan.

3649

JP¥804.00

-5.3%

-10.7%

Charm Care

JP¥40.0b

Engages in nursing care business.

6062

JP¥1,226.00

1.6%

2.9%